Research ArticleBasic Science Investigations
Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model
Gabriela Kramer-Marek, Merel Gijsen, Dale O. Kiesewetter, Ruth Bennett, Ioannis Roxanis, Rafal Zielinski, Anthony Kong and Jacek Capala
Journal of Nuclear Medicine April 2012, 53 (4) 629-637; DOI: https://doi.org/10.2967/jnumed.111.096685
Gabriela Kramer-Marek
Merel Gijsen
Dale O. Kiesewetter
Ruth Bennett
Ioannis Roxanis
Rafal Zielinski
Anthony Kong
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 53, Issue 4
April 1, 2012
Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model
Gabriela Kramer-Marek, Merel Gijsen, Dale O. Kiesewetter, Ruth Bennett, Ioannis Roxanis, Rafal Zielinski, Anthony Kong, Jacek Capala
Journal of Nuclear Medicine Apr 2012, 53 (4) 629-637; DOI: 10.2967/jnumed.111.096685
Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model
Gabriela Kramer-Marek, Merel Gijsen, Dale O. Kiesewetter, Ruth Bennett, Ioannis Roxanis, Rafal Zielinski, Anthony Kong, Jacek Capala
Journal of Nuclear Medicine Apr 2012, 53 (4) 629-637; DOI: 10.2967/jnumed.111.096685
Jump to section
Related Articles
Cited By...
- Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
- Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine
- Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
- Molecular Imaging Reveals Trastuzumab-Induced Epidermal Growth Factor Receptor Downregulation In Vivo
- First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
- Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies
- Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment
- Reply: PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model
- PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model